ArticleCardiovascular diabetology2021

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.

Chia-Te Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.